Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 103,200 shares, an increase of 47.9% from the September 15th total of 69,800 shares. Based on an average trading volume of 1,640,000 shares, the short-interest ratio is currently 0.1 days. Approximately 3.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC purchased a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Price Performance

NASDAQ:ALZN opened at $1.66 on Monday. The firm has a 50-day moving average of $2.19 and a 200-day moving average of $4.49. Alzamend Neuro has a one year low of $1.40 and a one year high of $33.57.

Alzamend Neuro (NASDAQ:ALZN) last posted its earnings results on Wednesday, September 11th. The company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($2.38) by $1.13. As a group, sell-side analysts expect that Alzamend Neuro will post -14.27 EPS for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.